Biofrontera AG - 16 Sep 2025 Form 4 Insider Report for Biofrontera Inc. (BFRI)

Role
Director, 10%+ Owner
Signature
/s/ Maria del Pilar de la Huerta Martinez, as Chief Financial Officer of Biofrontera AG
Issuer symbol
BFRI
Transactions as of
16 Sep 2025
Net transactions value
$0
Form type
4
Filing time
18 Sep 2025, 11:59:26 UTC
Previous filing
09 Jul 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Biofrontera AG Director, 10%+ Owner HEMMELRATHER WEG 201, LEVERKUSEN, GERMANY /s/ Maria del Pilar de la Huerta Martinez, as Chief Financial Officer of Biofrontera AG 18 Sep 2025 0001712641

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BFRI Series D Convertible Preferred Stock Purchase +3,019 3,019 16 Sep 2025 Common Stock 4,831,172 $0.000600 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The convertible preferred stock is convertible at any time, at the holder's election, and has no expiration date.
F2 The reporting person acquired the convertible preferred stock in a privately negotiated transaction in exchange for assets related to the production and sale of certain products in the United States having an estimated market value of approximately $3,019,000.

Remarks:

The Reporting Person has entered into an agreement with the Issuer pursuant to which the Reporting Person may appoint one representative to the board of directors of the Issuer. Dr. Heikki Lanckriet has been deputized to represent the Reporting Person on the board of directors of the Issuer. By virtue of Dr. Lanckriet's representation, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, the Reporting Person may be deemed a director by deputization of the Issuer. Dr. Lanckriet has filed a separate Section 16 report disclosing securities of the Issuer he may be deemed to beneficially own for Section 16 purposes.